Is either Cerebrolysin or citicoline FDA-approved?

No. Cerebrolysin is marketed in Russia, Eastern Europe, China and parts of Asia; not FDA-approved; unregistered across most of the EU. Citicoline is a US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia.

Which has stronger human evidence, Cerebrolysin or citicoline?

Neither clearly. Both have human clinical data. The key source for Cerebrolysin is Cerebrolysin for acute ischemic stroke, Cochrane 2023; for citicoline, it is ICTUS trial, Lancet 2012.

What are the main safety concerns with Cerebrolysin and citicoline?

With Cerebrolysin, Cochrane flagged a possible increase in non-fatal serious adverse events after stroke. Citicoline is well tolerated, with no safety signal in thousands of patients at high doses.

Head-to-head

Cerebrolysin vs Citicoline

Two compounds given for stroke and cognitive decline, both with real trials — and both with a null result sitting at the center of the record.

By Julian RothResearch & dataUpdated October 2026

Short answer

Cerebrolysin and citicoline both have human clinical data, so the deciding factor is what you want them for. Cerebrolysin suits someone focused on cognitive decline, stroke recovery and dementia, while citicoline is aimed at memory, focus and brain health. In trials, Cerebrolysin showed no significant difference vs placebo on the primary endpoint in CASTA, a 1,070-patient stroke trial.

Cerebrolysin

Clinical data

A porcine-brain-derived peptide mixture with a real but weak and mixed human trial record in stroke and dementia — not FDA-approved, and a recent Cochrane-style review found the evidence insufficient to recommend it.

Full Cerebrolysin evidence review

Citicoline

CDP-choline, Cognizin

Clinical data

The best-tested compound on the nootropic shelf, and that is the problem: ICTUS in stroke and COBRIT in brain injury were both null, leaving open-label cognition data and two small manufacturer-linked trials in healthy people.

Full Citicoline evidence review

Cerebrolysin vs Citicoline: head to head

FDA status / approved use: Cerebrolysin
Marketed in Russia, Eastern Europe, China and parts of Asia; not FDA-approved; unregistered across most of the EU
Citicoline
US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia
Marketed for: Cerebrolysin
Cognitive decline, stroke recovery, dementia
Citicoline
Memory, focus, brain health
Outcome areas: Cerebrolysin
Cognitive function / memory
Citicoline
Cognitive function / memory
Evidence grade: Cerebrolysin
Clinical data
Citicoline
Clinical data
How it works: Cerebrolysin
Pig-brain peptide fragments thought to mimic the brain's own neurotrophic factors
Citicoline
Supplies choline and uridine, which cells use to rebuild CDP-choline for membranes
Route and dosing: Cerebrolysin
Injection or intravenous infusion
Citicoline
Oral pill
Headline human result: Cerebrolysin
No significant difference vs placebo on the primary endpoint in CASTA, a 1,070-patient stroke trial
Citicoline
No benefit in acute ischemic stroke; the 2012 ICTUS trial of 2,298 patients was stopped for futility
Strongest evidence: Cerebrolysin
Cerebrolysin for acute ischemic stroke, Cochrane 2023Cerebrolysin evidence reviewPubMed 37818733
Citicoline
ICTUS trial, Lancet 2012Citicoline evidence reviewPubMed 22691567
Key safety signal: Cerebrolysin
Cochrane flagged a possible increase in non-fatal serious adverse events after stroke
Citicoline
Well tolerated, with no safety signal in thousands of patients at high doses
How it is obtained: Cerebrolysin
Not established
Citicoline
Over the counter as a dietary supplement

	Cerebrolysin	Citicoline
FDA status / approved use	Marketed in Russia, Eastern Europe, China and parts of Asia; not FDA-approved; unregistered across most of the EU	US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia
Marketed for	Cognitive decline, stroke recovery, dementia	Memory, focus, brain health
Outcome areas	Cognitive function / memory	Cognitive function / memory
Evidence grade	Clinical data	Clinical data
How it works	Pig-brain peptide fragments thought to mimic the brain's own neurotrophic factors	Supplies choline and uridine, which cells use to rebuild CDP-choline for membranes
Route and dosing	Injection or intravenous infusion	Oral pill
Headline human result	No significant difference vs placebo on the primary endpoint in CASTA, a 1,070-patient stroke trial	No benefit in acute ischemic stroke; the 2012 ICTUS trial of 2,298 patients was stopped for futility
Strongest evidence	Cerebrolysin for acute ischemic stroke, Cochrane 2023Cerebrolysin evidence reviewPubMed 37818733	ICTUS trial, Lancet 2012Citicoline evidence reviewPubMed 22691567
Key safety signal	Cochrane flagged a possible increase in non-fatal serious adverse events after stroke	Well tolerated, with no safety signal in thousands of patients at high doses
How it is obtained	Not established	Over the counter as a dietary supplement

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:: Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Neither earns the confidence its marketing carries, and they fail differently. Citicoline is the best-tested compound on the nootropic shelf, which is precisely the problem: ICTUS in stroke and COBRIT in brain injury were both null, leaving open-label cognition data and two small manufacturer-linked trials in healthy people. Cerebrolysin, a porcine-brain-derived peptide mixture, has a real but weak and mixed record in stroke and dementia, is not FDA-approved, and a Cochrane review found the evidence insufficient to recommend it. Citicoline was tested properly and did not work; cerebrolysin has not been tested well enough to say.

Cerebrolysin fits if

You are reviewing it as the registered drug it is in the countries that license it, not as a supplement.

Citicoline fits if

You want the compound with the largest and cleanest trials behind it, and you read two null pivotal results as the answer.

Cerebrolysin vs Citicoline: common questions

Is either Cerebrolysin or citicoline FDA-approved?: No. Cerebrolysin is marketed in Russia, Eastern Europe, China and parts of Asia; not FDA-approved; unregistered across most of the EU. Citicoline is a US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia.
Which has stronger human evidence, Cerebrolysin or citicoline?: Neither clearly. Both have human clinical data. The key source for Cerebrolysin is Cerebrolysin for acute ischemic stroke, Cochrane 2023; for citicoline, it is ICTUS trial, Lancet 2012.
What are the main safety concerns with Cerebrolysin and citicoline?: With Cerebrolysin, Cochrane flagged a possible increase in non-fatal serious adverse events after stroke. Citicoline is well tolerated, with no safety signal in thousands of patients at high doses.

Key studies behind each

Cerebrolysin

Ziganshina LE, Abakumova T, Nurkhametova D, et al. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. PubMed 37818733
Muresanu DF, Heiss WD, Hoemberg V, et al. (2016). Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. PubMed 26564102
Heiss WD, Brainin M, Bornstein NM, et al. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. PubMed 22282884
Cui S, Chen N, Yang M, et al. (2019). Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. PubMed 31710397

Citicoline

Wurtman RJ, Regan M, Ulus I, Yu L. (2000). Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. PubMed 10974208
Secades JJ, Gareri P. (2022). Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. PubMed 36544369
Dávalos A, Alvarez-Sabín J, Castillo J, et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. PubMed 22691567
Zafonte RD, Bagiella E, Ansel BM, et al. (2012). Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. PubMed 23168823

The full evidence reviews

Cerebrolysin: what it is, and what the evidence actually shows
A porcine-brain-derived peptide mixture sold abroad for stroke and dementia — and pitched online as a nootropic. A straight read of the Cochrane reviews and the regulatory reality.
Updated August 2026
Citicoline (CDP-choline): what the evidence actually shows
A prescription neuro-drug in dozens of countries and a supplement in the US — whose two largest, most rigorous trials, in stroke and brain injury, both came back null.
Updated August 2026

Related comparisons

Citicoline vs Huperzine A